Bone marrow mesenchymal stem cell (BMSCs)-based therapy seems to be a promising treatment for acute lung injury, but the therapeutic effects of BMSCs transplantation on acute lung injury induced by brain ischemia and the mechanisms have not been totally elucidated. This study explores the effects of transplantation of BMSCs on acute lung injury induced by focal cerebral ischemia and investigates the underlying mechanism. Acute lung injury model was induced by middle cerebral artery occlusion (MCAO). BMSCs (with concentration of 1 × 106/ml) were transplanted into host through tail vein 1 day after MCAO. Then, the survival, proliferation and migration of BMSCs in lung were observed at 4 days after transplantation, and histology observation and lung function were assessed for 7 days. Meanwhile, in situ hybridization (ISH), qRT-PCR and western blotting were employed to detect the expression of TNF-α in lung. Neurobehavioral deficits and acute lung injury could be seen in brain ischemia rats. Implanted BMSCs could survive in the lung, and relieve pulmonary edema, improve lung function, as well as down regulate TNF-α expression. The grafted BMSCs can survive and migrate widespread in lung and ameliorate lung injury induced by focal cerebral ischemia in the MCAO rat models. The underlying molecular mechanism, at least partially, is related to the suppression of TNF-α.
Background: The purpose of this study is to investigate the expression of nerve growth factor (NGF) in the lung injury induced by cerebral ischemia.Methods: Adult healthy female Sprague‐Dawley rats were randomly divided into two groups: sham group and brain ischemia (BI) induced lung injury group. Lung injury was induced by BI and neurological severity score (NSS) was evaluated. Triphenyltetrazolium chloride (TTC) staining, brain edema, ratio of wet/dry of lung tissue, hematoxylin‐eosin (HE) staining, as well as pulmonary edema were measured, respectively. The expression of mRNA and protein of NGF in lung tissues was detected by qPCR and western blot at 14 days post injury respectively. The immunohistochemical method was used to localize the expression of NGF in the lung tissues.Results: Lung injury from BI was successfully induced. The localization of NGF was detected mainly in the lung epithelial tissue following BI, also in vascular endothelial tissues. Compared with the sham group, the expression level of mRNA and protein for NGF was increased significantly after BI.Conclusion: The increase of NGF in the lung tissue after BI showed that NGF has been involved in the repair of injured lung, and the underlying mechanism of BI induced lung injury.
Objective Spinal cord transection (SCT), one of the common spinal cord injuries (SCI), could induce motor and behavioral deficits. With the deep understanding of SCI, there are certain progresses in the field of basic and clinical research, but these results are far from satisfaction due to the complex mechanism. Particularly, the gene expression have shown an important role the development of SCI. Thus modifying the gene expression may be a potential therapeutical target for SCI. This study is designed to investigate the gene map in transected spinal cord. Methods SCT model was established by the spinal cord transection at the segment of T10. Modified Basso, Beattie, and Bresnahan (BBB) scores were used to evaluate the motor function of rats. Then, microarray analysis was performed to screen the gene expression profile after 14 days. The intensity ratio > 2 or < 0.05 were regarded as differentially expressed genes. Genes ontology analysis including BP, CC and MF, were used to analyze the function and pathway of these genes. Results After SCT, the BBB scores were significantly lower than that of the sham group. Microarray analysis showed that there were 3059 upregulate genes and 3320 downregulated genes in spinal cord of SCT group. Analysis of these genes showed that cellular response to stimulus, staphylococcus aureus infection, glutamatergic synapse etc, participated in the SCI process. Conclusion These findings showed SCT regulated multiple gene expression, which might be associated with the multiple pathological changes. These further indicated that the occurrence of SCI was not a single gene or a single factor, but a complex pathophysiological process.
Malignancy is a fatal disease with an increasing incidence with each passing year, and the early diagnosis of malignancy can significantly improve the cure rate of patients, which has profound implications for saving patients' lives. The changes of miRNA are closely related to the occurrence of malignant tumors. The expression of miRNA in many malignant tumors is obviously different and unique from that in normal tissues. In this study, a strategy for amplifying microRNA (miRNA) signal was designed using duplex specific nuclease (DSN), which was then combined with Peptide nucleic acid (PNA) probe hybridization technology to prepare a sensitive and efficient paper-based lateral flow biosensor (LFB) for the detection of pancreatic cancer (PC) associated microRNA-10b. The performance evaluation results of the LFB showed that the detection limit of miR-NA-10b is 5 nM/mL, and carries demonstrated well specificity, stability, reproducibility. The biosensor prepared in this paper can provide accurate and rapid detection of miRNA-10b. The detection results play a guiding role in the early diagnosis of PC. Meeting the clinical need for largescale screening of individuals at high risk of PC. Providing new avenues to achieve early mass screening in individuals at high risk of PC.
Background: Spinal cord contusion (SCC) results in a series of pathophysiologic consequences such as edema, apoptosis, and inflammation. However, inflammation may also be beneficial for the recovery of motor function after SCC, but the underlying mechanisms remain incompletely elucidated. Interleukin-1 beta (IL-1β) is a pro-inflammatory factor that has synergistic effects with other inflammatory factors to aggravate spinal cord injury. Inflammatory factors have been found to activate the serine/threonine-specific protein kinase, protein kinase B (AKT) and to inhibit cell survival, but it is not clear whether inflammation upregulates the expression of IL-1β in the rat model of SCC and subsequently interferes in the phosphatidylinositol-3-kinase (PI3K)/AKT signaling pathway. Therefore, this study explored whether IL-1β affects the recovery of motor function in spinal cord injury by interfering with the PI3K/AKT signaling pathway. Method: SCC rats were established by the Allen method. The Basso Beattie Bresnahan (BBB) scoring was used to assess motor function in the spinal cord of injured rats. Quantitative polymerase chain reaction and Western blot were used to determine the expression of genes and proteins of IL-1β, PI3K, and AKT1. Immunohistochemistry and immunofluorescence were used to locate and detect IL-1β and AKT1 proteins in spinal cord tissue. To further explore the underlying mechanism of IL-1β, lentivirus was constructed by RNA interfering (RNAi) technique to inhibit the expression of IL-1β, and bioinformatics was applied to show the relationship between IL-1β and AKT1. Results: BBB scores decreased after SCC, and IL-1β and AKT1 was located in the cytoplasm of spinal cord anterior horn neurons. In the early stage of SCC, the expression level of IL-1β gene and protein in the experimental group was higher than that in the sham operated group. At the same time, expression of the AKT1 gene decreased. After expression of IL-1β mediated by lentivirus was inhibited, BBB scores increased significantly, and spinal cord motor function improved. Bioinformatic analysis revealed a relationship between IL-1β and AKT1. In addition, AKT1 gene expression was upregulated and PI3K expression was unchanged in the PI3K/AKT signaling pathway. Conclusion IL-1β not only exacerbates the inflammatory response after SCC, but also interferes with motor function. Inhibition of IL-1β may promote recovery of spinal cord injury by upregulating AKT1 in the PI3K/AKT signaling pathway, which provides a new perspective for future clinical practice in treating spinal cord injury